Emerging Clinical Signals

Excerpt from Custom Post Type Indication: ECS

Pre-ESMO 2025 Analyst Briefing

Antibody Drug Conjugates

Medical Conference Coverage SGO: April 11-13, 2026 AACR: April 17-22, 2026 ASCO: May 29 – June 2, 2026 EHA: June 11-14, 2026 WCLC: September 12-15, 2026 ESMO: October 23-27, 2026 SNO: November 12-15, 2026 SABCS: December 8-11, 2026 ASH: December 12-15, 2026  ASCO GU: February 11-13, 2027 ELCC: March 17-20, 2027 ICML: June 15-19, 2027 […]

DNA Damage Response

The DNA damage response (DDR) field has seen major advances in recent years, particularly in ovarian, breast, prostate, and pancreatic cancers. Most cancers depend on DNA damage detection and repair for survival and are thus vulnerable to targeted inhibition of DDR proteins. DDR therapies include inhibitors of PARP, ATR, WEE1, and DNA-PK. The DDR field […]

Non-Hodgkin’s Lymphoma

Excerpt from Custom Post Type Indication: NHL

Myeloproliferative Neoplasms

Excerpt from Custom Post Type Indication: MPNs

Multiple Myeloma

Excerpt from Custom Post Type Indication: MM

Myelodysplastic Syndromes

Excerpt from Custom Post Type Indication: MDS

Chronic Lymphocytic Leukemia

Excerpt from Custom Post Type Indication: CLL

Acute Myeloid Leukemia

Excerpt from Custom Post Type Indication: AML

Acute Lymphoblastic Leukemia

Excerpt from Custom Post Type Indication: ALL

Cell Therapies

Excerpt from Custom Post Type Indication: Cell Therapies

Immuno-Oncology: Late Stage

Excerpt from Custom Post Type Indication: Immuno-Oncology: Late Stage

Soft Tissue Sarcoma

Excerpt from Custom Post Type Indication: STS

Melanoma

Excerpt from Custom Post Type Indication: Melanoma

Head and Neck Squamous Cell Carcinomas

Excerpt from Custom Post Type Indication: H&N

Gliomas

Excerpt from Custom Post Type Indication: Gliomas

Ovarian

Excerpt from Custom Post Type Indication: Ovarian

Endometrial

Excerpt from Custom Post Type Indication: Endometrial

Breast Cancer

Excerpt from Custom Post Type Indication: Breast

Small Cell Lung Cancer

Excerpt from Custom Post Type Indication: SCLC

Non-small Cell Lung Cancer

Excerpt from Custom Post Type Indication: NSCLC

Renal Cell Carcinoma

Excerpt from Custom Post Type Indication: RCC

Prostate Cancer

Excerpt from Custom Post Type Indication: Prostate

Bladder Cancer

Excerpt from Custom Post Type Indication: Bladder

Pancreatic

Excerpt from Custom Post Type Indication: Pancreatic

Hepatocellular Carcinoma

Excerpt from Custom Post Type Indication: HCC

Gastric Cancer

Excerpt from Custom Post Type Indication: Gastric

Esophageal

Excerpt from Custom Post Type Indication: Esophageal

Colorectal

Excerpt from Custom Post Type Indication: CRC

Immuno-Oncology: Emerging

Excerpt from Custom Post Type Indication: Immuno-Oncology: Emerging

Sarah Lockhead, Ph.D.

Therapy Area Director, Oncology

Stacey Aggarwal, Ph.D.

Disease Area Manager, Oncology

Carla Cabrera Johnson, Ph.D.

Senior Manager, Oncology